FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

PURPOSE: Activating FGFR2 mutations have been identified in ~10% of endometrioid endometrial cancers (ECs). We have previously reported that mutations in FGFR2 are associated with shorter disease free survival (DFS) in stage I/II EC patients. Here we sought to validate the prognostic importance of F...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Gynecol Oncol
Главные авторы: Jeske, Yvette W., Ali, Shamshad, Byron, Sara A, Gao, Feng, Mannel, Robert S, Ghebre, Rahel G, DiSilvestro, Paul A, Lele, Shashikant B, Pearl, Michael L, Schmidt, Amy P, Lankes, Heather A, Ramirez, Nilsa C, Rasty, Golnar, Powell, Matthew, Goodfellow, Paul J, Pollock, Pamela M
Формат: Artigo
Язык:Inglês
Опубликовано: 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5433848/
https://ncbi.nlm.nih.gov/pubmed/28314589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.02.031
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы